Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

✍ Scribed by Christina Davies

• Book ID: 116394910
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 248 KB
• Volume: 30
• Category: Article
• ISSN: 0305-7372
• DOI: 10.1016/j.ctrv.2004.06.005